Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 3/20 | 0.32 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30352336 | 0.92 | — | — | |
| SCHEMBL16785310 | 0.86 | — | — | |
| SCHEMBL11403219 | 0.78 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL2565188 | 0.74 | — | — | |
| SCHEMBL15942714 | 0.74 | ALDH1A1 (0.46) | ALDH1A1 | |
| SCHEMBL3330004 | 0.74 | MEN1 (0.31) | — | |
| SCHEMBL4041858 | 0.74 | — | — | |
| SCHEMBL4127530 | 0.73 | ALDH1A1 (0.36) | ALDH1A1PDE4APDE7A | |
| SCHEMBL491578 | 0.73 | ALDH1A1 (0.36) | ALDH1A1PDE4APDE7A | |
| SCHEMBL5459307 | 0.73 | ALDH1A1 (0.36) | ALDH1A1PDE4APDE7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140073651-A1 | BENZAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-03-13 | — | — | US | disclosed |
| EP-2608669-A1 | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-07-03 | — | — | EP | disclosed |
| WO-2012027236-A1 | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | SCHERING CORPORATION (US) | 2012-03-01 | — | — | WO | disclosed |
| CN-1518445-A | Treatment of sexual dysfunction | 沃纳-兰伯特公司 | 2004-08-04 | — | — | CN | disclosed |
| CN-1479618-A | Treatment of sexual dysfunction with bombesin antagonists | ����-�����ع�˾ | 2004-03-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073651-A1 | BENZAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | P2RX3, P2RX7, P2RX1 | ALDH1A1 1255/4885GAA 2309/4885PDE4A 1049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.